In October 2021, the FDA approved Susvimo, a port delivery system (PDS) developed by Genentech (South San Francisco, CA, USA), for the treatment of exudative AMD in eyes that had previously received at least two anti-VEGF injections [113]. The gene discussed is VEGFA; the disease is age-related macular degeneration.